Hospital Care Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hospital care deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of hospital care deals from 2016 to 2023.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of hospital care dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in hospital care dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the hospital care field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in hospital care dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of hospital care deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of hospital care deals listed by theraeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in hospital care deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Hospital Care Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Fully revised and updated, the report provides details of hospital care deals from 2016 to 2023.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of hospital care dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in hospital care dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the hospital care field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in hospital care dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of hospital care deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of hospital care deals listed by theraeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in hospital care deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Hospital Care Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse hospital care collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report scope
Hospital Care Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of hospital care trends and structure of deals entered into by leading biopharma companies worldwide.Hospital Care Collaboration and Licensing Deals includes:
- Trends in hospital care dealmaking in the biopharma industry
- Overview of collaboration and licensing deal structure
- Directory of hospital care deal records covering pharmaceutical and biotechnology
- The leading hospital care deals by value
- Most active hospital care licensing dealmakers
In Hospital Care Collaboration and Licensing Deals, the available deals are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
Hospital Care Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in hospital care dealmaking
Chapter 3 - Financial deal terms for hospital care partnering
Chapter 4 - Leading hospital care deals and dealmakers
Chapter 5 - Hospital care contract document directory
Chapter 6 - Hospital care dealmaking by therapeutic target
Deal Directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3D-Side
- 3D Systems
- 3M
- 3SBio
- 4WEB Medical
- 7 Hills Pharma
- 7D Surgical
- 11 Health and Technologies
- 111
- A&E Medical
- AAP Implantate AG
- Aatru Medical
- Abbvie
- Abiomed
- Ab Medica
- Abram Scientific
- Absolute Antibody
- AbSorber
- Acacia Pharma
- Acacia Research
- Acare Medical Science
- Accelus
- Accenture
- Access Scientific
- Accord Healthcare
- Accuray
- AccuTec Blades
- Acelity
- Acell
- Acelrx Pharmaceuticals
- Acentrus Specialty
- Acerus
- ActLight
- Acuity Healthcare
- Acuna-Fombona
- AdaptHealth
- Adaptimmune
- ADAS 3D Medical
- Adeor Medical
- Adhezion Biomedical
- ADIENNE Pharma & Biotech
- Admedus
- Advanced Aesthetic Technologies
- Advanced Cooling Therapy
- Advanced Guidance Technologies
- Advanced IT Concepts
- Advanced Ultrasound Systems
- Advantage Medical
- Advanz Pharma
- AdventHealth
- Aerapy
- Aerobiotix
- Aesculap
- Aesthetic Management Partners
- Aesthetic Medical International
- Aethlon Medical
- Aetna
- Agadia Systems
- AgeX Therapeutics
- Agiliti
- AgNovos Healthcare
- Aguettant
- Aidoc
- Aiforia Technologies
- AirStrip Technologies
- AirXpanders
- Aitrics
- Akari Therapeutics
- Akers Biosciences
- Akumin
- ALASTIN Skincare
- Alfasigma
- Algeos
- AliMed
- AliveCor
- ALK-Abello
- Allegheny Technologies
- Allenex
- Allergan
- Allergan Aesthetics
- Alliance Medical
- Allied Centre for Medical Excellence
- Alliqua Biomedical
- Alloksys Life Sciences
- AlloSource
- Almirall
- Alnylam Pharmaceuticals
- Alpha Imaging
- Alphamedix
- Alphatec Spine
- Altan Pharma
- Altaris Capital Partners
- Altasciences
- Altitude International
- Alume Biosciences
- Alvarado Hospital Medical Center
- Alyzen Medical Physics
- Amag Pharmaceuticals
- Ambra Health
- Ambu
- Amedica
- Amedisys
- Amendia
- Amend Surgical
- American Academy of Orthopaedic Surgeons
- American College of Chest Physicians
- American Health Imaging
- American Medical Technologies
- American Society for Aesthetic Plastic Surgery
- American Well
- Amerinet
- AmerisourceBergen
- Amgen
- AMI
- Amicrobe
- AMNIOX
- Amomed Pharma
- Amplifire
- Amplyx Pharmaceuticals
- Ancestry
- Anelixis Therapeutics
- Anelto
- Angiodynamics
- Angion Biomedica
- Angsana Molecular & Diagnostics
- Anika Therapeutics
- Anita Tecnica
- ANP Technologies
- Antares Pharma
- Anthem
- Antibe Therapeutics
- Apex Physics Partners
- ApiFix
- Apollo Endosurgery
- Appalachian Regional Healthcare
- Apple
- Applied DNA Sciences
- Applimotion
- APR Medtech
- Aptevo Therapeutics
- Archer Capital
- Arch Therapeutics
- argenx
- Argon Medical Devices
- Aridea Solutions
- Aridis Pharmaceuticals
- Arjo
- Arkansas Childrens Hospital
- Armaghan Salamat Kish
- Armis Biopharma
- Armor
- Arsenal Medical
- Artegraft
- Arteriocyte Medical Systems
- Arthrex
- Arthrosurface
- ARxIUM
- Asahi Kasei
- Ascendum
- Ascension
- Ascension Saint Thomas
- Asensus Surgical
- ASICO
- AskAt
- Asklepios Group
- Aspen Surgical Products
- Assure
- Astarte Medical
- Astellas Pharma
- AstraZeneca
- Asys
- Athersys
- Atlas Lift Tech
- ATL Technology
- Atnahs Pharma
- Atos Medical
- Atricure
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
